
TRPV6 Channels

Claudia Fecher-Trost, Petra Weissgerber, and Ulrich Wissenbach

Contents

1	Gene	360
1.1	Splice Variants and Polymorphisms	361
1.2	Initiation of Translation from a Non-AUG Codon	361
2	Expression	363
2.1	Transcriptional Regulation of <i>Trpv6</i> by Vitamin D ₃	364
2.2	Transcriptional Regulation of <i>Trpv6</i> by Steroid Hormones	365
2.3	Transcriptional Regulation of <i>Trpv6</i> by Other Hormones	366
3	The Channel Protein Including Structural Aspects	366
4	TRPV6-Interacting Proteins	367
5	Biophysical Properties of TRPV6 Channels	369
6	Pharmacology of TRPV6 Channels	370
7	Physiological Functions of TRPV6	370
7.1	TRPV6 Channels in Bone	371
7.2	TRPV6 Channels in Placenta	371
8	Lessons from Knockouts	372
9	Roles in Hereditary and Acquired Disease	374
	References	376

Abstract

TRPV6 (former synonyms ECAC2, CaT1, CaT-like) displays several specific features which makes it unique among the members of the mammalian *Trp* gene family (1) TRPV6 (and its closest relative, TRPV5) are the only highly Ca²⁺-selective channels of the entire TRP superfamily (Peng et al. 1999; Wissenbach et al. 2001; Voets et al. 2004). (2) Translation of *Trpv6* initiates at a non-AUG codon, at ACG, located upstream of the annotated AUG, which is not used for initiation (Fecher-Trost et al. 2013). The ACG codon is nevertheless decoded by

C. Fecher-Trost • P. Weissgerber • U. Wissenbach (✉)
Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Universität des Saarlandes, 66421 Homburg, Germany
e-mail: ulrich.wissenbach@uks.eu

methionine. Not only a very rare event in eukaryotic biology, the full-length TRPV6 protein existing *in vivo* comprises an amino terminus extended by 40 amino acid residues compared to the annotated truncated TRPV6 protein which has been used in most studies on TRPV6 channel activity so far. (In the following numbering occurs according to this full-length protein, with the numbers of the so far annotated truncated protein in brackets). (3) Only in humans a coupled polymorphism of *Trpv6* exists causing three amino acid exchanges and resulting in an ancestral *Trpv6* haplotype and a so-called derived *Trpv6* haplotype (Wissenbach et al. 2001). The ancestral allele encodes the amino acid residues C₁₉₇₍₁₅₇₎, M₄₁₈₍₃₇₈₎ and M₇₂₁₍₆₈₁₎ and the derived alleles R₁₉₇₍₁₅₇₎, V₄₁₈₍₃₇₈₎ and T₇₂₁₍₆₈₁₎. The ancestral haplotype is found in all species, the derived *Trpv6* haplotype has only been identified in humans, and its frequency increases with the distance to the African continent. Apparently the *Trpv6* gene has been a strong target for selection in humans, and its derived variant is one of the few examples showing consistently differences to the orthologues genes of other primates (Akey et al. 2004, 2006; Stajich and Hahn 2005; Hughes et al. 2008). (4) The *Trpv6* gene expression is significantly upregulated in several human malignancies including the most common cancers, prostate and breast cancer (Wissenbach et al. 2001; Zhuang et al. 2002; Fixemer et al. 2003; Bolanz et al. 2008). (5) Male mice lacking functional TRPV6 channels are hypo-/infertile making TRPV6 one of the very few channels essential for male fertility (Weissgerber et al. 2011, 2012).

Keywords

Calcium selective channel • Non AUG translation start • Prostate cancer • Breast cancer • Male fertility • Polymorphism • Epithelial calcium transport

1 Gene

The *Trpv6* gene is located on chromosome 7q33-q34 (human), chromosome 6 (mouse) and chromosome 4 (rat) in close proximity to its closest relative, *Trpv5* (7q35 in human). The deduced protein sequences comprise ~75 % identical amino acids (Peng et al. 1999, 2000; Hoenderop et al. 1999; Muller et al. 2000; Wissenbach et al. 2001; Hirnet et al. 2003). *Trpv5* and *Trpv6* arose by gene duplication from an ancestral gene, and the pufferfish *Takifugu rubripes*, for example, has only one gene which is slightly more similar to *Trpv6* than to *Trpv5* (Qiu and Hogstrand 2004; Peng 2011). The TRPV5 gene is mainly expressed in the kidney of mammals, whereas *Trpv6* has a broader expression pattern. Therefore, it was speculated that gene duplication reflects the complex renal situation of land-living animals (Peng 2011). The *Trpv5-6*-like genes can be identified in primitive eukaryotic organisms like the choanoflagellate *Monosiga brevicollis* (King et al. 2008). In general *Trpv5-6*-like genes are not present in prokaryotic organisms,

protocysts, fungi and plants. However, the green algae *Chlamydomonas reinhardtii* and *Volvox carteri* exhibit *Trpv5-6*-like genes, and this may reflect horizontal gene transfer at a comparatively late time point during the evolution of these algae (Merchant et al. 2007). The chromosomal organization of *Trpv6* is conserved among several species. In the mouse genome *Trpv6* spans 15 exons and extends over a region of ~15.7 kb. Depending on the species, the deduced amino acid sequence is in the range of 703–767 amino acids.

1.1 Splice Variants and Polymorphisms

To date there are no splice variants known for human and mouse *Trpv6*. But in humans two alleles of the *Trpv6* gene were identified (Wissenbach et al. 2001): one ancestral variant (*Trpv6a*, red in Fig. 1a, b) and a so-called derived variant (*Trpv6b*, yellow in Fig. 1a, b). The cDNA sequences of the two alleles differ in five bases resulting in three amino acid substitutions with R₁₉₇₍₁₅₇₎, V₄₁₈₍₃₇₈₎ and T₇₂₁₍₆₈₁₎ in the derived variant and C₁₉₇₍₁₅₇₎, M₄₁₈₍₃₇₈₎ and M₇₂₁₍₆₈₁₎ in the ancestral variant. Additional polymorphisms found within the intronic regions of the *Trpv6* gene seem to be coupled to those polymorphisms in the coding region (Kessler et al. 2009). The frequencies of the two *Trpv6* alleles are highly variable between different ethnic groups. The percentage of the ancestral *Trpv6a* allele decreases with increasing distance to the African continent (Akey et al. 2006). In a few South African populations, the *Trpv6a* allele frequency is higher than 50 % of the tested alleles and decreases to less than 5 % in East Asian populations. From these data, it was assumed that a so far unknown selection pressure leads to the higher allele frequency of the *Trpv6b* variant in non-African humans (Akey et al. 2004; Stajich and Hahn 2005; Soejima et al. 2009). The physiological consequence of the polymorphisms is not clear yet. After heterologous expression of the *Trpv6a* and *Trpv6b* cDNAs, a non-significant faster Ca²⁺-dependent inactivation of TRPV6b channels was noted (Hughes et al. 2008), but in general both channel variants revealed very similar biophysical properties (ion selectivity, reversal potential, Ca²⁺-dependent inactivation, Mg²⁺ block). After *Trpv6* cRNA injection into *Xenopus laevis* oocytes, current amplitudes (measured as amplitudes of endogenous Ca²⁺-activated Cl⁻ currents) (Sudo et al. 2010) or ⁴⁵Ca²⁺ uptake (Suzuki et al. 2008b) were larger for TRPV6a than for TRPV6b. Unfortunately, the latter publication lacks adequate controls. Interestingly, Akey et al. (2004) speculated that strong selection on the *Trpv6* locus is correlated to milk consumption and lactase persistence.

1.2 Initiation of Translation from a Non-AUG Codon

Recently our group showed (Fecher-Trost et al. 2013) that the full-length endogenous human TRPV6 protein is 40 amino acid residues longer at the N terminus as previously thought (Fig. 1c). Translation starts at an ACG codon upstream of the




Fig. 1 (a) Structure of the TRPV6 channel non-synonymous polymorphisms are indicated: ancestral TRPV6a (red) and the derived variant TRPV6b (yellow). P-1, phosphorylation sites for *src* kinase (P-1, tyrosine₁₆₁), for PTP1B phosphatase (P-1) and for protein kinase C (P-2, threonine₇₄₂). Below numbering of the amino acids of the full-length TRPV6 (black) and the truncated annotated TRPV6 (grey). Protein interaction sites are indicated (see also Table 1 and text). (b) Multiple alignment of the non-synonymous polymorphism shown in (a), among several species (V6) aligned with the corresponding amino acid sequences of TRPV5 (V5). The derived TRPV6b variant (yellow) is only present in humans. The amino acid residues in TRPV5 proteins correspond to the amino acids present in TRPV6a. (c) Translation initiation of the full-length TRPV6 protein occurs at an ACG which is decoded by methionine and which is localized upstream of the annotated AUG codon

first AUG of the *Trpv6* mRNA. Although ACG codons are normally translated into threonine (T), the translational machinery incorporates methionine (M) instead. Translation of a non-AUG codon into methionine is a rare event, and to our knowledge, only the testis-specific PRPS3 protein (ribose-phosphate pyrophosphokinase 3, NM_175886.2) is also initiated from an ACG codon which

is apparently decoded by methionine (Taira et al. 1990). Alignments of the annotated 5'-untranslated *Trpv6* sequences indicate that in mammals but not in non-mammals, the TRPV6 protein appears to be translated from an ACG codon upstream of the annotated AUG. Accordingly, the murine TRPV6 protein also comprises a longer N terminus, and the initiation triplet is most likely the corresponding ACG codon (Fecher-Trost et al. 2013). Furthermore, analysis of 5' regions of other *Trpv* genes indicates that translation initiation from an upstream non-AUG codon is an exclusive feature of *Trpv6* which is not met by any other *Trpv* including *Trpv5*.

2 Expression

The murine *Trpv6* is expressed in placenta, pancreas, prostate, epididymis and several parts of the small intestine including duodenum, oesophagus, stomach, colon, kidney and uterus as demonstrated by RT-PCR and Northern blots (Hirnet et al. 2003; Weissgerber et al. 2011, 2012; Lehen'kyi et al. 2012). Compared to mouse there are some differences of the *Trpv6* expression in humans. First, expression of *Trpv6* within small intestine (including duodenum) has not consistently been shown, and second, whereas *Trpv6* is highly expressed in the murine prostate, it is much less expressed in the human prostate; however, it is clearly overexpressed in prostate cancer as shown by Northern blots analysis and in situ hybridization (Wissenbach et al. 2001, 2004; Peng et al. 2001; Fixemer et al. 2003). *Trpv6* appears to be expressed in various cancer cell lines, but direct identification of the TRPV6 protein by mass spectrometry has only been shown in the human breast cancer cell line T47D (Fecher-Trost et al. 2013) and in the human lymph node prostate cancer cell line LNCaP (Fecher-Trost, Wissenbach, and Flockerzi, unpublished data).

In murine kidney only low levels of mRNA were detected by Northern blots and RT-PCR (Hirnet et al. 2003; Song et al. 2003; Peng 2011), but in immunostains the TRPV6 protein was identified in the apical domain of the distal convoluted tubules, in connecting tubules and cortical and medullary collecting ducts (Nijenhuis et al. 2003; Hoenderop et al. 2003a). In rat and in human kidney, *Trpv6* transcripts are not detectable by Northern blots (Peng et al. 1999; Wissenbach et al. 2001; Brown et al. 2005), but fragments of *Trpv6* transcripts could be weakly amplified in human kidney by RT-PCR (Peng et al. 2000; Hoenderop et al. 2001). Apparently, different age, variability of Ca²⁺ and vitamin D within the food and the hormonal state may confound detection of *Trpv6* expression in kidney (Lee et al. 2004; Hoenderop et al. 2005) and also in duodenum. In summary, data from Northern blots consistently confirm *Trpv6* expression in rat small intestine, in human and mouse placenta, pancreas and to a lower extent in the intestine, in human prostate cancer, in mouse placenta and in mouse epididymis. The *Trpv6* cDNAs were originally cloned from rat intestine (Peng et al. 1999) and human placenta (Wissenbach et al. 2001). Using antibodies which discriminate between corresponding tissues from wild-type and *Trpv6*-deficient mice, TRPV6 proteins have been identified in human placenta (Stumpf et al. 2008; Fecher-Trost

et al. 2013), mouse prostate and epididymis (Weissgerber et al. 2011, 2012); by mass spectrometry TRPV6 proteins were directly identified in placenta and the human cancer cell lines T47D (Fecher-Trost et al. 2013) and LNCaP cells.

2.1 Transcriptional Regulation of *Trpv6* by Vitamin D₃

Intestinal Ca²⁺ absorption (Bronner et al. 1986a, b) depends on two major pathways, a paracellular pathway and a transcellular pathway which can be stimulated by vitamin D₃ (Bronner and Pansu 1999; Bronner 2003; Kellett 2011; Lieben and Carmeliet 2012). The transcellular pathway includes a Ca²⁺ uptake channel at the luminal/apical membrane, soluble cytosolic Ca²⁺-binding proteins and a Ca²⁺ extrusion mechanism at the basal membrane (Hoenderop et al. 2005; Suzuki et al. 2008c); a similar pathway appears to be relevant in placenta (Brunette 1988; Lafond et al. 1991; Belkacemi et al. 2002, 2003, 2004). Initial findings revealed that the amounts of *Trpv6* transcripts in the rat duodenum detected by Northern blots were not changed by prior treatment of the rats by 1,25-dihydroxyvitamin D₃ or by feeding them a Ca²⁺-deficient diet (Peng et al. 1999), arguing that *Trpv6* expression is not regulated by vitamin D₃ or calcium deficiency in duodenum. In contrast, treatment of Caco-2 cells, a human epithelial colorectal adenocarcinoma cell line, by 1,25-dihydroxyvitamin D₃ upregulates *Trpv6* expression (Wood et al. 2001). In addition, *Trpv6* transcript levels were decreased in vitamin D receptor-deficient mice (Okano et al. 2004), whereas 1,25-dihydroxyvitamin D₃ supplementation of 25-hydroxyvitamin D₃-1 α -hydroxylase-deficient mice, which have undetectable levels of endogenous 1,25-dihydroxyvitamin D₃ and suffer from hypocalcaemia, resulted in increased expression of TRPV6, calbindin-D9K and PMCA1b and normalization of serum Ca²⁺ (van Abel et al. 2003). Binding sites for 1,25-dihydroxyvitamin D₃ and enhancer regions within the *Trpv6* promoter have been identified and characterized in detail (Pike et al. 2007), and it was concluded that transcellular Ca²⁺ uptake involves TRPV6 channels at the luminal intestinal side as primary Ca²⁺ uptake mechanism. Intracellular Ca²⁺ is then bound to calbindin 9K and transported across the cell to the basolateral side where it is extruded through the plasma membrane Ca²⁺-ATPase (PMCA1b) and the Na⁺/Ca²⁺ exchanger (van Abel et al. 2003). However, this model had to be reconsidered by the finding that duodenal Ca²⁺ uptake is normal in *Calbindin 9K*-deficient mice (Lee et al. 2007). In *Calbindin 9K*-/*Calbindin 28K*-double knockout mice, serum Ca²⁺ levels and bone length were decreased only under a low Ca²⁺ diet (Ko et al. 2009). In the *Trpv6*-deficient (Bianco et al. 2007; Kutuzova et al. 2008) and in the *Trpv6*^{D/A/D/A} knock-in mouse lines (Weissgerber et al. 2011; Woudenberg-Vrenken et al. 2012), respectively, no functional TRPV6 channels are expressed; intestinal Ca²⁺ uptake was not affected in both lines (Kutuzova et al. 2008; Woudenberg-Vrenken et al. 2012) at a normal Ca²⁺ diet; at a low Ca²⁺ diet, intestinal Ca²⁺ uptake was slightly decreased in the *Trpv6*^{D/A/D/A} knock-in mice. The finding that 1,25-dihydroxyvitamin D₃ administration increases intestinal Ca²⁺ uptake in *Trpv6*-deficient mice and in

Trpv6/Calbindin 9K-deficient double knockout mice put into question that TRPV6 and calbindin 9K are essential for vitamin D-induced active intestinal calcium transport (Benn et al. 2008). So in summary, it appears that *Trpv6* expression is regulated by vitamin D₃, but the TRPV6 channel is not the essential component of intestinal Ca²⁺ uptake; instead it might rather be involved in mechanisms preventing the loss of Ca²⁺ already present in the organism by reabsorbing Ca²⁺ (see also TRPV6 functions in mouse epididymis and prostate below).

2.2 Transcriptional Regulation of *Trpv6* by Steroid Hormones

Duodenal *Trpv6* (and *Trpv5*) expression was shown to be upregulated in ovariectomized rats after 17 β -estradiol supplementation (van Abel et al. 2003), and in *oestrogen receptor*-deficient mice, duodenal *Trpv6* transcripts were reduced (Van Cromphaut et al. 2003). Decreased *Trpv6* transcript levels were also seen in an *aromatase*-deficient mouse line (Oz et al. 2007), a model of oestrogen deficiency. Ca²⁺ uptake of *Xenopus laevis* oocytes injected with the *Trpv6* cRNA (Bolanz et al. 2008) was reduced by the selective oestrogen receptor modulator tamoxifen. Similarly, basal cytosolic Ca²⁺ levels which were higher in the human breast cancer cell line MCF-7 which has been transfected with a *Trpv6* cDNA in comparison with non-transfected cells were also reduced in the presence of tamoxifen (Bolanz et al. 2009). Interestingly, this effect could be also demonstrated in the oestrogen receptor-negative MDA-MB-231 cells (Bolanz et al. 2009). Apparently, *Trpv6* expression may be regulated independently by oestrogen receptors and by tamoxifen. In the human breast cancer cell line T47D, the only breast cancer cell line in which the TRPV6 protein has been directly identified so far (Fecher-Trost et al. 2013), *Trpv6* expression appears to be increased in the presence of estradiol, progesterone and 1,25-dihydroxyvitamin D₃ and to be reduced in the presence of tamoxifen (Bolanz et al. 2008).

Duodenal Ca²⁺ uptake in mice was decreased after prednisolone treatment (Huybers et al. 2007) which resulted in reduced *Calbindin 9K* and *Trpv6* transcript expression in duodenum. Accordingly, it was concluded that reduced bone mineral density as unwanted effect from glucocorticoid treatment could result from downregulation of *Trpv6*. However, 5 days of dexamethasone administration affected bone metabolism, but expression levels of *Trpv6*, *calbindin 9K* and *PMCA1b* were not significantly different from tissues of untreated animals (Van Cromphaut et al. 2007). In contrast, dexamethasone-dependent downregulation of *Trpv6* was reported when five times higher dexamethasone doses had been applied (Kim et al. 2009a, b). Little or no expression of *Trpv6* was found in a variety of human and murine osteoblastic cells using qPCR (Little et al. 2011), indicating that TRPV6 plays no pivotal role in bone mineralization. These data are fully consistent with the data obtained from the *Trpv6*^{D/A/D/A} mouse line (Weissgerber et al. 2011), which lacks functional TRPV6 channels, and did not show alterations of bone metabolism and bone matrix mineralization (van der Eerden et al. 2012).

In LNCaP, expression of *Trpv6* was shown to be upregulated in the presence of an androgen receptor antagonist whereas dihydrotestosterone reduced expression (Peng et al. 2001), but treatment of these cells did not affect Ca^{2+} entry (Bodding et al. 2003). Additional conditions have been reported to enhance *Trpv6* transcript expression including hypoxic conditions in human placenta (Yang et al. 2013) and developmental upregulation in intestine of neonatal mice at weaning (Song et al. 2003) which appeared to depend on vitamin D_3 and during pregnancy (Lee and Jeung 2007) but still occurs in *vitamin D receptor*-deficient mice (Van Cromphaut et al. 2003).

2.3 Transcriptional Regulation of *Trpv6* by Other Hormones

Intestinal Ca^{2+} absorption has been shown to be upregulated during pregnancy and lactation independent of vitamin D_3 (Boass et al. 1981; Brommage et al. 1990; Halloran and DeLuca 1980) or of the vitamin D receptor (Van Cromphaut et al. 2003). In accordance with these observations, prolactin had been shown to enhance intestinal Ca^{2+} absorption in vitamin D_3 -deficient rats, to directly stimulate the transcellular Ca^{2+} transport in duodenal preparations (Charoenphandhu et al. 2001; Pahuja and DeLuca 1981) and to regulate vitamin D metabolism and induction of *Trpv6* mRNA expression (Ajibade et al. 2010).

During pregnancy, an active Ca^{2+} transport through the placenta (Sibley and Boyd 1988) was found to be regulated by the parathyroid hormone-related protein PTHrP (Tobias and Cooper 2004). In *PTHrP*-deficient mice, significant differences in placental Ca^{2+} transport compared to wild-type mice were observed, but the transcript levels of *Trpv6* and plasma membrane Ca^{2+} ATPase (*Pmca*) 1 and 4 were unaltered (Bond et al. 2008; Karaplis et al. 1994) arguing against transcriptional regulation of *Trpv6* and *Pmca* by PTHrP.

3 The Channel Protein Including Structural Aspects

The endogenous human full-length TRPV6 protein consists of 765 amino acids (accession number KF534785; Fecher-Trost et al. 2013) compared to the 725-aa annotated TRPV6 protein, which is truncated. The additional 40-aa sequence shows no similarity to any known protein sequence; nine out of the 40 amino acid residues are proline residues, and they might well constitute motifs involved in protein–protein interaction mediated by SH3 domains. The N terminus contains a series of 6 repeats with similarity to domains found in ankyrin repeat proteins (Wissenbach et al. 2001). Erler et al. (2004) identified ankyrin repeat 3 and 5 as critical components involved in the assembly of functional channel complexes. The crystal structure of the six ankyrin repeat domains (aa 124–345 or aa 84–305 in the truncated version) revealed conserved helical-turn-helix conformations, very similar to those present in TRPV1 and 2, but with a variable long-loop region between ankyrin repeat 3 and 4 (Phelps et al. 2008). Various short intracellular C-terminal

fragments of TRPV6 (and TRPV5) were used for circular dichroism (CD) and NMR spectroscopy in the presence and absence of calmodulin, and the results obtained suggest an association of calmodulin and the TRPV6 C terminus (Kovalevskaia et al. 2011, 2012).

TRPV6 proteins most likely co-assemble to homotetrameric channels. Heterotetrameric TRPV6/TRPV5 channels have been reported after co-expression of the respective cRNAs in oocytes (Hoenderop et al. 2003b), but the *in vivo* expression pattern of both genes does hardly overlap. An exception might be the kidney, where both genes are expressed, but *Trpv5* expression is much more abundant than *Trpv6* (van Abel et al. 2005). TRPV6 proteins are glycosylated at Asn 397 (357) which is located within the extracellular S1–S2 linker (Hirnet et al. 2003; Chang et al. 2005). The beta-glucuronidase klotho stimulates TRPV6 (and TRPV5) channel activity by sugar hydrolysis at the Asn 397 glycosylation site which is conserved in the TRPV5 protein (Chang et al. 2005). The higher expression of klotho within kidney tissue might be an indicator that *in vivo* the target for klotho-dependent regulation is TRPV5 (Kuro-o et al. 1997).

4 TRPV6-Interacting Proteins

Studies were performed using yeast two-hybrid screens, pull-down assays and antibody-based affinity purifications from primary tissues and HEK cells expressing the TRPV6 cDNA to identify proteins which are transiently or stably associated with TRPV6. A few proteins have been identified including calmodulin, klotho, S100A10-annexin 2, the PDZ domain-containing protein Na⁺/H⁺ exchanger regulatory factor 4 (NHERF4) and Rab11a which regulate the trafficking, plasma membrane anchoring and activity of the TRPV6 channel. The TRPV6-binding sites for these proteins have been mapped within extracellular and intracellular linkers of transmembrane regions and within the cytosolic C- and N-termini of TRPV6 (Fig. 1a, Table 1).

Calmodulin is known to regulate TRPV6 channel activity, and strong evidence exists for a functional high-affinity calmodulin association at the C terminus of human/mouse TRPV6 between aa 735 and 756 (Niemeyer et al. 2001; Hirnet et al. 2003; Derler et al. 2006; Cao et al. 2013). The calcium-dependent calmodulin binding to the C terminus facilitates channel inactivation and is counteracted by protein kinase C-mediated phosphorylation within the calmodulin-binding site at threonine residue 742 (Niemeyer et al. 2001). Stumpf and co-workers used the high-affinity binding of TRPV6 for calmodulin to copurify TRPV6 and interacting proteins from human placenta with a calmodulin column (Stumpf et al. 2008).

The C-terminal high-affinity calmodulin-binding site is also sensitive for phosphatidylinositol 4,5-bisphosphate (PIP₂) binding (Zakharian et al. 2011; Cao et al. 2013), which interferes with the binding of calmodulin and inversely regulates TRPV6 activity, but presumably not through a direct competition mechanism. The latter study shows a complex interplay between calmodulin and PIP₂ and

Table 1 TRPV6-interacting proteins

Protein	Putative function	References
Calmodulin	Channel inactivation/modulation	Niemeyer et al. (2001), Hirnet et al. (2003), Lambers et al. (2004), Derler et al. (2006), Stumpf et al. (2008), Kovalevskaya et al. (2012)
	Competitive PIP2/calmodulin regulation	Cao et al. (2013), Zakharian et al. (2011)
Klotho	Activation through increase of plasma membrane level	Chang et al. (2005)
Calbindin D28K	Binding	Lambers et al. (2006)
BSPRY	Binding	van de Graaf et al. (2006b, c)
PKC	Competitive regulation of calmodulin-dependent inactivation	Niemeyer et al. (2001)
PTBIP, SRC	Channel inhibition	Sternfeld et al. (2007)
Cyclophilin B	Channel activation	Stumpf et al. (2008)
NHERF	Protein transport to plasma membrane, activation	Kim et al. (2007)
Rab11a	Protein transport to plasma membrane, channel activation	van de Graaf et al. (2006a)
Nipsnap1	Channel inhibition	Schoeber et al. (2008)
RGS2	Channel inhibition	Schoeber et al. (2006)
S100A10	Increase in plasma membrane level, activation	Borthwick et al. (2008), van de Graaf et al. (2003)
TRPC1	Suppression of plasma membrane targeting, inhibition of TRPV6 activity	Schindl et al. (2012), Courjaret et al. (2013)
TRPV5	Heterooligomerization, binding	Hellwig et al. (2005), Hoenderop et al. (2003a), Semenova et al. (2009)

demonstrates that calcium, calmodulin and the depletion of PIP2 contribute to the inactivation of TRPV6 channels.

Three additional calmodulin-binding sites have been reported (Lambers et al. 2004), N- and C-terminal and within the intracellular S2–S3 linker (see Fig. 1), but their functions have not been confirmed (Derler et al. 2006; Cao et al. 2013). In addition, the presumed N-terminal calmodulin-binding site forms a part of the ankyrin repeat core domain and is therefore unlikely to serve as calmodulin interaction site (Phelps et al. 2008). In line with this, Derler and co-workers show that the N terminus is not involved in channel inactivation by calmodulin (Derler et al. 2006).

Hydrolysis of the extracellular N-linked sugar residues at asparagine 397 by the glucuronidase klotho (see above) entraps the channel proteins in the plasma membrane (Chang et al. 2005) and, as a consequence, results in a higher channel activity. Klotho is the first mammalian proteo-hormone, which binds to TRPV6 from the extracellular side. Replacing the asparagine residue by a glutamine and thereby

creating a glycosylation-deficient TRPV6 mutant abolished klotho-dependent channel activation. The stimulatory effect of klotho is restricted to TRPV5 and TRPV6 and not detectable for TRPV4 and TRPM6, which are also expressed in the kidney (Lu et al. 2008).

In summary, some TRPV6-interacting proteins, like calmodulin or klotho, have been investigated by several studies, and it has been shown consistently that they modulate/regulate channel activity, whereas most of the other candidate proteins were only reported with little or without biochemical or functional characterization (see also <http://trpchannel.org/summaries/TRPV6>).

5 Biophysical Properties of TRPV6 Channels

TRPV6 (and TRPV5) represent Ca^{2+} -selective ion channels (Peng et al. 1999; Nilius et al. 2000; Vennekens et al. 2000; Wissenbach et al. 2001; Hirnet et al. 2003). Under physiological conditions, TRPV6 conducts only Ca^{2+} ions, but in the absence of divalent cations, the channel conducts monovalents such as Na^+ (Vennekens et al. 2000; Nilius et al. 2001; Wissenbach et al. 2001; Voets et al. 2003). Interestingly, Na^+ currents do not inactivate, whereas Ca^{2+} currents quickly inactivate indicating a Ca^{2+} -dependent inactivation mechanism (Hoenderop et al. 2005). Another mechanism of inactivation includes the hydrolysis of phosphatidylinositol 4,5-bisphosphate (Thyagarajan et al. 2008). Al-Ansary and co-workers mapped an ATP binding site in the N-terminal region of the TRPV6 protein which indicates that the channel is regulated by the cytosolic ATP concentration (Al-Ansary et al. 2010). The channel permeability was estimated to be about 100 times more selective for Ca^{2+} than for Na^+ , and the single aspartate residue D581 in the murine TRPV6 (D541 in the truncated protein) and D582 in the human TRPV6 (D542 in the truncated protein) were identified to be part of the selectivity filter (Nilius et al. 2001, 2003; Voets et al. 2003, 2004; Vennekens et al. 2008). In the absence of Ca^{2+} , TRPV6 also conducts Mg^{2+} and the initially large currents quickly inactivate (Voets et al. 2001, 2003). Depending on the membrane potential, Mg^{2+} ions block and unblock the channel pore (Voets et al. 2003) and influence the inward rectification behaviour of TRPV6. Some inward rectification also appears in the absence of Mg^{2+} and seems to be an intrinsic property of TRPV6 (Hoenderop et al. 2005). TRPV6 and TRPV5 conduct Ba^{2+} , but the permeability and inactivation properties of Ba^{2+} currents are different between TRPV6 and TRPV5 although the pore sequences are identical (Nilius et al. 2002; Hoenderop et al. 2005). Also Cd^{2+} and Zn^{2+} can permeate and contribute to the toxicity of these heavy metal ions (Kovacs et al. 2013). Interestingly, Ba^{2+} -dependent current properties seem to be determined by residues in the transmembrane regions 2 and 3 indicating that structures quite distant to the pore region may influence pore properties as well as the inactivation behaviour of the channel.

The single channel conductance of TRPV6 was estimated to be 40–70 pS, and by cysteine scanning the pore width was calculated to be 5.4 Å (Hoenderop et al. 2001, 2005; Voets et al. 2004). Apparently, most of the electrophysiological data

described were obtained from HEK293 cells overexpressing the truncated *Trpv6* cDNA. The comparison of the biophysical properties of channels obtained after expressing the full-length cDNA or the truncated cDNA yields very similar results so far (Fecher-Trost et al. 2013). However, the full-length TRPV6 is more efficiently translocated to the plasma membrane, and five times more of the truncated TRPV6 protein is required to produce similar current amplitudes (Fecher-Trost et al. 2013).

Another yet unsolved problem is that in acutely isolated primary cells which do endogenously express *Trpv6* transcripts like pancreatic acinar cells, TRPV6-like currents could not be recorded although the protocols applied yield impressive currents in HEK293 cells expressing the *Trpv6* cDNA. Instead, in primary cells and tissues, $^{45}\text{Ca}^{2+}$ uptake measurements are the method of choice to monitor TRPV6 activity. Using this method TRPV6 activity was identified in epididymal epithelia (Weissgerber et al. 2011, 2012).

6 Pharmacology of TRPV6 Channels

Xestospongins C, a natural isolate from a sponge (Vassilev et al. 2001), inhibits TRPV6 in the lower μM range. Ruthenium red also blocks TRPV6 but works more potently on TRPV5 (Hoenderop et al. 2001). Some antifungal drugs such as econazole and miconazole inhibit TRPV5 and TRPV6 (Hoenderop et al. 2001). A newly synthesized derivative of a substance called TH-1177 inhibits TRPV6 currents with an IC_{50} for TRPV6 of $0.44 \mu\text{M}$ (Haverstick et al. 2000; Landowski et al. 2011). This compound is five times more effective on TRPV6 than on TRPV5. 2-APB (2-aminoethoxydiphenyl borate), a rather non-selective TRP channel blocker/activator, was shown to block TRPV6 but surprisingly not TRPV5 (Kovacs et al. 2012). Recently a peptide, soricidin, derived from short-tailed shrew (Bowen et al. 2013) was shown to exhibit an analgesic effect and to suppress growth of some tumour cells. It was shown that the C-terminal part of the peptide is sufficient for growth inhibition, and the authors demonstrate that one target of this peptide is TRPV6: TRPV6 currents in HEK293 cells are partially blocked with an IC_{50} in the low nM range. Apparently, soricidin represents the most potent TRPV6 channel blocker [see also Owsianik et al. (2006) and Vennekens et al. (2008)].

7 Physiological Functions of TRPV6

Since the identification and the cloning of the cDNAs and the initial expression studies, both TRPV6 and TRPV5 have been implicated in epithelial Ca^{2+} uptake. In agreement with this function, the *Trpv6* gene was shown to be expressed in placenta, pancreas, salivary gland and several parts of the small intestine including duodenum by Northern blots and in situ hybridization (Peng et al. 1999; Wissenbach et al. 2001; Hirnet et al. 2003). Using antibodies for TRPV6, immunostaining was demonstrated in enterocytes of the intestinal villi in the

murine duodenum with predominant expression at the apical cell membrane at the tips of the villi (Little et al. 2011) as well as in exocrine organs including pancreas, prostate and mammary gland (Zhuang et al. 2002). In addition, the TRPV6 protein was detected within the mouse kidney at the apical domain of the late distal convoluted tubule, the connecting tubule and the cortical and medullary collecting ducts (Nijenhuis et al. 2003). Several groups demonstrated the expression of TRPV6 in the proximal part of duodenum (Zhuang et al. 2002; van de Graaf et al. 2003; Walters et al. 2006; Huybers et al. 2007) in line with a role for TRPV6 in intestinal Ca^{2+} absorption, but others did not detect *Trpv6* expression in duodenum and kidney (Wissenbach et al. 2001).

Appropriate controls for antibody specificity including immunostains from knockout mice strongly support results in general, but have not been described in most studies referred to above. One of the few exceptions is the demonstration that TRPV6 proteins are expressed in the apical membrane of the murine epididymal epithelium and prostatic epithelium (Weissgerber et al. 2011, 2012). It should be mentioned here that expression of *Trpv6* transcripts in human prostate is low or even not detectable depending on the method (Northern blot, in situ hybridization or PCR) but is upregulated in human prostate cancer (see below).

7.1 TRPV6 Channels in Bone

Laser scanning microscopy revealed that TRPV6 proteins—as well as TRPV5—are expressed at the apical domain of murine osteoclasts cultured on cortical bone slices predominantly at the bone-facing site (van der Eerden et al. 2005). However, TRPV6 activity did not compensate the reduced bone resorption occurring in mice lacking *Trpv5* (Hoenderop et al. 2003c). Additional immunohistochemical analysis revealed only weak staining for TRPV6 in osteoblasts and no staining in cortical or trabecular osteocytes nor in the growth plate (Little et al. 2011), whereas *Trpv6* mRNA was detectable in the murine bone (Nijenhuis et al. 2003) with considerable expression in the bone marrow.

7.2 TRPV6 Channels in Placenta

The *Trpv6* mRNA was detected in syncytiotrophoblasts (Wissenbach et al. 2001) and uterus (Moreau et al. 2002) suggesting a role for basal Ca^{2+} influx in placental cells and from there to the foetus. Whereas the placental Ca^{2+} transport and the involved proteins are not completely understood, so far TRPV6 protein was decreased in placenta from women suffering from pre-eclampsia compared to healthy placental tissue (Hache et al. 2011). Pre-eclampsia (PE) is a multisystemic disorder that represents a major factor for maternal and perinatal mortality, and it affects 7–10 % of pregnancies worldwide (Sibai 2005; Walker 2000). In mice, *Trpv6* is highly expressed in the extraplacental yolk sac (the foetal side of the placenta) and only weakly expressed on the maternal side of the placenta during the last

trimester of gestation, but *Trpv6* transcript expression was strongly upregulated from embryonic day 15 to day 18 (Suzuki et al. 2008a) indicating involvement in the increase of maternal-foetal Ca^{2+} transport which supports foetal bone mineralization.

8 Lessons from Knockouts

At present, three independent mouse lines exist with targeted germ line mutations within the *Trpv6* gene (Bianco et al. 2007; Weissgerber et al. 2011). One *Trpv6*-deficient line was generated using a classical knockout strategy replacing exons 9–15 and exons 15–18 of the adjacent *Ephb6* gene by a neomycin resistance cassette (Bianco et al. 2007). In an independent approach, a Cre-loxP strategy was used to delete exons 13–15 of *Trpv6* encoding part of transmembrane domain 5, the pore, the transmembrane domain 6, the cytosolic C terminus and exons 17–18 of the *Ephb6* gene (Weissgerber et al. 2012). For homologous recombination, genomic sequences of appropriate length are required within the gene-targeting vector, and this is the reason that deletion of the exons 13–15 of the *Trpv6* gene also affected parts of the closely adjacent *Ephb6* gene. In a third mouse line, a single aspartate (D) residue at position 581 (541 in the truncated protein) within the pore region was replaced by an alanine (A) residue (*Trpv6*^{D/A/D/A}). This residue is a critical constituent of the TRPV6 selectivity filter, and replacement by an alanine (D/A) completely abolished the Ca^{2+} permeability (Nilius et al. 2001; Voets et al. 2004; Weissgerber et al. 2012).

Bianco et al. (2007) reported that their *Trpv6*^{-/-} mice were viable but show decreased intestinal Ca^{2+} absorption, lower femoral bone mineral density, lower body weight, growth retardation and reduced fertility of homozygous males and females, and 80 % of all mice developed alopecia and dermatitis (Table 2). Serum Ca^{2+} levels were normal, but under Ca^{2+} -restricted conditions, the *Trpv6*^{-/-} mice developed hypocalcaemia. Furthermore, the total Ca^{2+} levels in the serum and amniotic fluid of *Trpv6*^{-/-} foetus were significantly lower than those in wild-type foeti (Bianco et al. 2007; Suzuki et al. 2008a). Analysis of active intestinal Ca^{2+} transport revealed no difference between *Trpv6*^{-/-} and wild-type mice on a standard diet (Benn et al. 2008).

The analysis of the *Trpv6*^{-/-} and the *Trpv6*^{D/A/D/A} mice from Weissgerber et al. (2011, 2012) demonstrated that homozygous males but not females from both mouse lines showed severely impaired fertility despite normal copulation behaviour. Furthermore, the spermatozoa showed markedly reduced motility, fertilization capacity and viability. Northern blot and immunohistochemical analysis demonstrated that *Trpv6* was expressed in the apical membrane of the epididymal epithelium but not in spermatozoa or the germinal epithelium. The Ca^{2+} concentration within the fluid of the cauda epididymis was significantly increased in both mouse lines *Trpv6*^{D/A/D/A} and *Trpv6*^{-/-} compared to wild-type controls and led to reduced sperm viability. These results indicate that appropriate Ca^{2+} concentration is essential for the development of viable and fertilization-competent spermatozoa. In addition, deletion of the *Trpv6* gene (Weissgerber et al. 2012) did not further

Table 2 Comparison of *TRPV6*^{D/A/D/A} and *Trpv6*-deficient mouse lines

Analysed parameter	<i>Trpv6</i> ^{D/A/D/A} (Weissgerber et al. 2011)	<i>Trpv6</i> ^{-/-} (Weissgerber et al. 2012)	<i>Trpv6</i> ^{-/-} (Bianco et al. 2007)
Femoral bone mineral density	No difference	Not analysed	Decreased
Body weight	No difference	No difference	Decreased in homozygous males and females
Growth retardation	Not detectable	Not detectable	Decreased in homozygous males and females
Fertility defect	Homozygous males	Homozygous males	Homozygous males and females
Sperm motility	Impaired	Impaired	Not analysed
Sperm viability	Impaired	Impaired	Not analysed
Ca ²⁺ homeostasis			
<i>On normal calcium diet:</i>			
–Intestinal Ca ²⁺ absorption	No change	Not analysed	Decreased
–Serum PTH and 1,25-dihydroxyvitamin D	Not analysed	Not analysed	Elevated
–Urine osmolality	Not analysed	Not analysed	Altered
–Ca ²⁺ excretion	No change	No change	Increased
–Polyuria	No change	No change	Increased
–Serum Ca ²⁺ level	No change	No change	No change
<i>On Ca²⁺ restricted diet:</i>			
–Serum Ca ²⁺ level	Unaltered	Not analysed	Decreased (hypocalcaemia)
–Intestinal Ca ²⁺ uptake	Decreased	Not analysed	Decreased
Alopecia	Not detectable	Not detectable	Yes
Dermatitis	Not detectable	Not detectable	Yes

aggravate the phenotype observed in *TRPV6*^{D/A/D/A} mice (Weissgerber et al. 2011), arguing against residual channel activity of the mutated *TRPV6*^{D/A} protein. *TRPV6* proteins were also identified in the apical epithelial membranes of prostatic epithelium, and *Trpv6* deletion results in Ca²⁺ precipitates within the enlarged prostatic ducts. Van der Eerden et al. (2011) showed that *Trpv6*^{D/A/D/A} mice do not have altered bone mass, and other morphological parameters such as trabecular and cortical bone microarchitecture were similar compared to wild-type mice. However, bone size was affected as shown by reductions in femoral length as well as femoral head, cortical bone and endocortical bone volumes. Intestinal Ca²⁺ uptake under a Ca²⁺-restricted diet was significantly impaired in *Trpv6*^{D/A/D/A} mice compared to wild-type mice (Woudenberg-Vrenken et al. 2012) demonstrating a specific role of *TRPV6* in transepithelial Ca²⁺ absorption under conditions of limited Ca²⁺ supplies.

Differences in Ca^{2+} absorption, weight gain, hair coat or fertility of homozygous females (Bianco et al. 2007) were not observed in the *Trpv6*^{-/-} or *Trpv6*^{D/A/D/A} mice generated by Weissgerber et al. (2011, 2012; Table 2). The reason for the discrepancies between the *Trpv6*-deficient mouse lines is not known, but different exons were deleted in either strategy and differences in the genetic background between the mouse lines cannot be excluded. In addition, the neo-cassette introduced for gene targeting has been removed from the mouse lines of Weissgerber et al. (2011, 2012) before phenotyping. If this foreign DNA remains in the genomic locus, it may influence the expression of neighbouring genes. Because it contains cryptic splice sites, its persisting presence can also fortuitously create a hypomorphic allele. Finally, the number of animals used to characterize a phenotype is crucial; for example, weight gain was studied with four animals (Bianco et al. 2007) and 19–31 animals (Weissgerber et al. 2011).

9 Roles in Hereditary and Acquired Disease

Changes of *Trpv6* transcript expression have been shown in various transgenic mouse models of human diseases (Table 3) but whether these changes occur in humans and whether there is a link between the changes of transcript expression and the pathophysiology of these diseases have only preliminarily been investigated. For example, Lowe disease patients carry mutations within the *phosphatidylinositol bisphosphate (PIP2) 5-phosphatase* gene resulting in increased levels of the substrate phosphatidylinositol 4,5-bisphosphate (PIP2), and this lipid accumulates in the renal proximal tubule cells of these patients (Devuyst and Thakker 2010). PIP2 positively regulates the activity of TRPV6 (Thyagarajan et al. 2008; Zakharian et al. 2011; Wu et al. 2012; Cao et al 2013) and might therefore contribute to the intestinal hyperabsorption of Ca^{2+} in these patients.

From the very beginning, it became apparent that *Trpv6* transcripts are overexpressed in cancerous tissue and in cell lines derived thereof (Table 4, and expression profiles HG-U95A and GDS1746 available at <http://www.ncbi.nlm.nih.gov/geo/profiles>). In prostate cancer, *Trpv6* transcripts are overexpressed and the expression pattern correlates with the aggressiveness of the disease (Wissenbach et al. 2001, 2004; Peng et al. 2001; Fixemer et al. 2003). Likewise, in the human lymph node prostate cancer cell line LNCaP, upregulation of *Trpv6* transcripts by vitamin D treatment enhanced proliferation rate and resistance to apoptosis (Lehen'kyi et al. 2007, 2011, 2012). The proliferation rate of HEK293 cells expressing the *Trpv6* cDNA was also enhanced (Schwarz et al. 2006). Nude mice in which HEK293 cells stably expressing *Trpv6* were injected subcutaneously as xenografts developed tumours (Wissenbach 2013), whereas control mice injected with non-transfected HEK293 cells or with HEK293 cells stably expressing *Trpc4* did not. As described above, soricidin (Bowen et al. 2013), a peptide isolated from the venom of the short-tailed shrew, inhibits TRPV6 currents. Tumours derived from injection of the ovarian cancer cell line SKOV-3 and the cell line DU145

Table 3 *Trpv6* expression in animal models of human disease

Animal model: disease	Link to <i>Trpv6</i>	References
<i>Slc26a4</i> knockout mouse: animal model for Pendred syndrome	Expression of <i>Trpv6</i> (and <i>Trpv5</i>) in the cochlea (immunohistochemistry)	Wangemann et al. (2007)
<i>TNF_{ΔARE}</i> mouse: animal model of Crohn's-like disease	Transcript ↓(qPCR, duodenum)	Huybers et al. (2008)
(<i>Cln5</i> knockout mouse: animal model of Dent disease)	(Mutations of <i>OCRL</i> cause Lowe syndrome and Dent disease) Co-expression of <i>Trpv6</i> (immunohistochemistry) and the oculocerebrorenal syndrome of Lowe (<i>OCRL</i>) gene product, the phosphatidylinositol 4,5-bisphosphate 5-phosphatase in rat Intestinum. In <i>Xenopus laevis</i> oocytes endogenous OCRL suppressed TRPV6-mediated Ca ²⁺ uptake	Wu et al. (2012)
<i>Slc12A3_{truncated}}</i> knock-in mouse: animal model of Gitelman syndrome	<i>Trpv6</i> transcript ↑(qPCR kidney)	Yang et al. (2010)
Hypercalciuric stone-forming (GHS) rat: animal model for kidney stones	<i>Trpv6</i> transcript ↑(qPCR, kidney)	Frick et al. (2013)

Table 4 *Trpv6* expression in malignant human tissues and cancer cell lines

Malignancy	Method	References
Prostate cancer	RT-PCR, Northern, ISH	Fixemer et al. (2003), Peng et al. (2001), Wissenbach et al. (2001, 2004)
LNCaP	Northern, Western	Bodding et al. (2003), Peng et al. (2001)
DU-145	RT-PCR	Lehen'kyi et al. (2011), Peng et al. (2001)
PC3	RT-PCR	Peng et al. (2001)
Breast cancer	RT-PCR, immunostaining ^a	Bolanz et al. (2008), Zhuang et al. (2002)
MCF7	RT-PCR, Western blot ^a	Bolanz et al. (2009)
T47D	MS/MS, RT-PCR	Bolanz et al. (2008), Fecher-Trost et al. (2013)
Colon cancer	Immunostaining ^a	Zhuang et al. (2002)
SW480	Northern	Peng et al. (2000)
LS-180	RT-PCR	Zheng et al. (2012)
Caco	RT-PCR, Western ^a	Fleet et al. (2002), Taparia et al. (2006)
Ovarian cancer	Immunostaining ^a	Zhuang et al. (2002)
SKOV-3	Peptide staining of xenograft	Bowen et al. (2013)
Thyroid cancer	Immunostaining ^a	Zhuang et al. (2002)
Endometrial cancer	ISH	Wissenbach and Niemeyer (2007)
Leukaemia	–	–
K-562	Northern	Peng et al. (2000), Semenova et al. (2009)

^aNo data available on antibody specificity

derived from brain metastases of prostate cancer could be stained with soricidin-derived peptides *in vivo* (Bowen et al. 2013) apparently through labelling TRPV6. In addition to prostate cancer, *Trpv6* transcripts are overexpressed in breast cancer and breast cancer-derived cell lines (Zhuang et al. 2002) as well as in oestrogen receptor-negative breast cancer tumours (Peters et al. 2012). The authors also showed that overexpression of *Trpv6* most likely results from genomic amplification of the *Trpv6* gene. Gene amplification of *Trpv6* was also found in prostate tumours (Kessler and Wissenbach, unpublished). In summary, the data indicate that overexpression of *Trpv6* is involved in carcinogenesis of several human cancers. They demonstrate the importance of TRPV6 which not only represent a marker for prostate cancer progression but may serve as a target for therapeutic strategies in the malignancies listed above.

References

- Ajibade DV, Dhawan P, Fechner AJ, Meyer MB, Pike JW, Christakos S (2010) Evidence for a role of prolactin in calcium homeostasis: regulation of intestinal transient receptor potential vanilloid type 6, intestinal calcium absorption, and the 25-hydroxyvitamin D(3) 1 α hydroxylase gene by prolactin. *Endocrinology* 151(7):2974–2984
- Akey JM, Eberle MA, Rieder MJ, Carlson CS, Shriver MD, Nickerson DA, Kruglyak L (2004) Population history and natural selection shape patterns of genetic variation in 132 genes. *PLoS Biol* 2(10):e286
- Akey JM, Swanson WJ, Madeoy J, Eberle M, Shriver MD (2006) TRPV6 exhibits unusual patterns of polymorphism and divergence in worldwide populations. *Hum Mol Genet* 15(13):2106–2113
- Al-Ansary D, Bogeski I, Disteldorf BM, Becherer U, Niemeyer BA (2010) ATP modulates Ca²⁺ uptake by TRPV6 and is counteracted by isoform-specific phosphorylation. *FASEB J* 24(2):425–435
- Belkacemi L, Simoneau L, Lafond J (2002) Calcium-binding proteins: distribution and implication in mammalian placenta. *Endocrine* 19(1):57–64
- Belkacemi L, Garipey G, Mounier C, Simoneau L, Lafond J (2003) Expression of calbindin-D28k (CaBP28k) in trophoblasts from human term placenta. *Biol Reprod* 68(6):1943–1950
- Belkacemi L, Garipey G, Mounier C, Simoneau L, Lafond J (2004) Calbindin-D9k (CaBP9k) localization and levels of expression in trophoblast cells from human term placenta. *Cell Tissue Res* 315(1):107–117
- Benn BS, Ajibade D, Porta A, Dhawan P, Hediger M, Peng JB, Jiang Y, Oh GT, Jeung EB, Lieben L, Bouillon R, Carmeliet G, Christakos S (2008) Active intestinal calcium transport in the absence of transient receptor potential vanilloid type 6 and calbindin-D9k. *Endocrinology* 149(6):3196–3205. doi:10.1210/en.2007-1655
- Bianco SD, Peng JB, Takanaga H, Suzuki Y, Crescenzi A, Kos CH, Zhuang L, Freeman MR, Gouveia CH, Wu J, Luo H, Mauro T, Brown EM, Hediger MA (2007) Marked disturbance of calcium homeostasis in mice with targeted disruption of the *Trpv6* calcium channel gene. *J Bone Miner Res* 22(2):274–285
- Boass A, Toverud SU, Pike JW, Haussler MR (1981) Calcium metabolism during lactation: enhanced intestinal calcium absorption in vitamin D-deprived, hypocalcemic rats. *Endocrinology* 109(3):900–907
- Bodding M, Fecher-Trost C, Flockerzi V (2003) Store-operated Ca²⁺ current and TRPV6 channels in lymph node prostate cancer cells. *J Biol Chem* 278(51):50872–50879

- Bolanz KA, Hediger MA, Landowski CP (2008) The role of TRPV6 in breast carcinogenesis. *Mol Cancer Ther* 7(2):271–279
- Bolanz KA, Kovacs GG, Landowski CP, Hediger MA (2009) Tamoxifen inhibits TRPV6 activity via estrogen receptor-independent pathways in TRPV6-expressing MCF-7 breast cancer cells. *Mol Cancer Res* 7(12):2000–2010
- Bond H, Dilworth MR, Baker B, Cowley E, Requena Jimenez A, Boyd RD, Husain SM, Ward BS, Sibley CP, Glazier JD (2008) Increased maternofetal calcium flux in parathyroid hormone-related protein-null mice. *J Physiol* 586(7):2015–2025
- Borthwick LA, Neal A, Hobson L, Gerke V, Robson L, Muimo R (2008) The annexin 2-S100A10 complex and its association with TRPV6 is regulated by cAMP/PKA/CnA in airway and gut epithelia. *Cell Calcium* 44(2):147–157
- Bowen CV, Debay D, Ewart HS, Gallant P, Gormley S, Ilenchuk TT, Iqbal U, Lutes T, Martina M, Mealing G, Merkley N, Sperker S, Moreno MJ, Rice C, Syvitski RT, Stewart JM (2013) In Vivo Detection of Human TRPV6-Rich Tumors with Anti-Cancer Peptides Derived from Soricidin. *PLoS One* 8(3):e58866
- Brommage R, Baxter DC, Gierke LW (1990) Vitamin D-independent intestinal calcium and phosphorus absorption during reproduction. *Am J Physiol* 259:G631–G638
- Bronner F (2003) Mechanisms of intestinal calcium absorption. *J Cell Biochem* 88:387–393
- Bronner F, Pansu D (1999) Nutritional aspects of calcium absorption. *J Nutr* 129:9–12
- Bronner F, Pansu D, Stein WD (1986a) Analysis of calcium transport in rat intestine. *Adv Exp Med Biol* 208:227–234
- Bronner F, Pansu D, Stein WD (1986b) An analysis of intestinal calcium transport across the rat intestine. *Am J Physiol* 250:G561–G569
- Brown AJ, Krits I, Armbrrecht HJ (2005) Effect of age, vitamin D, and calcium on the regulation of rat intestinal epithelial calcium channels. *Arch Biochem Biophys* 437:51–58
- Brunette MG (1988) Calcium transport through the placenta. *Can J Physiol Pharmacol* 66:1261–1269
- Cao C, Zakharian E, Borbiri I, Rohacs T (2013) Interplay between calmodulin and phosphatidylinositol 4,5-bisphosphate in Ca²⁺-induced inactivation of transient receptor potential vanilloid 6 channels. *J Biol Chem* 288:5278–5290
- Chang Q, Hoefs S, van der Kemp AW, Topala CN, Bindels RJ, Hoenderop JG (2005) The beta-glucuronidase klotho hydrolyzes and activates the TRPV5 channel. *Science* 310(5747):490–493
- Charoenphandhu N, Limlomwongse L, Krishnamra N (2001) Prolactin directly stimulates transcellular active calcium transport in the duodenum of female rats. *Can J Physiol Pharmacol* 79:430–438
- Courjaret R, Hubrack S, Daalis A, Dib M, Machaca K (2013) The Xenopus TRPV6 homolog encodes a Mg²⁺-permeant channel that is inhibited by interaction with TRPC1. *J Cell Physiol* 228:2386–2398
- Derler I, Hofbauer M, Kahr H, Fritsch R, Muik M, Kepplinger K, Hack ME, Moritz S, Schindl R, Groschner K, Romanin C (2006) Dynamic but not constitutive association of calmodulin with rat TRPV6 channels enables fine tuning of Ca²⁺-dependent inactivation. *J Physiol* 577:31–44
- Devuyst O, Thakker RV (2010) Dent's disease. *Orphanet J Rare Dis* 5:28
- Erler I, Hirnet D, Wissenbach U, Flockerzi V, Niemeyer BA (2004) Ca²⁺-selective transient receptor potential V channel architecture and function require a specific ankyrin repeat. *J Biol Chem* 279:34456–34463
- Fecher-Trost C, Wissenbach U, Beck A, Schalkowsky P, Stoerger C, Doerr J, Dembek A, Simon-Thomas M, Weber A, Wollenberg P, Ruppert T, Middendorff R, Maurer HH, Flockerzi V (2013) The in vivo TRPV6 protein starts at a non-AUG triplet decoded as methionine upstream the canonical initiation at AUG. *J Biol Chem* 288:16629–16644
- Fixemer T, Wissenbach U, Flockerzi V, Bonkhoff H (2003) Expression of the Ca²⁺-selective cation channel TRPV6 in human prostate cancer: a novel prognostic marker for tumor progression. *Oncogene* 22:7858–7861

- Fleet JC, Eksir F, Hance KW, Wood RJ (2002) Vitamin D-inducible calcium transport and gene expression in three Caco-2 cell lines. *Am J Physiol Gastrointest Liver Physiol* 283:G618–G625
- Frick KK, Asplin JR, Favus MJ, Culbertson C, Krieger NS, Bushinsky DA (2013) Increased biological response to 1,25(OH)₂D₃ in genetic hypercalciuric stone-forming rats. *Am J Physiol Renal Physiol* 304:F718–F726
- Hache S, Takser L, LeBellego F, Weiler H, Leduc L, Forest JC, Giguere Y, Masse A, Barbeau B, Lafond J (2011) Alteration of calcium homeostasis in primary preeclamptic syncytiotrophoblasts: effect on calcium exchange in placenta. *J Cell Mol Med* 15:654–667
- Halloran BP, DeLuca HF (1980) Calcium transport in small intestine during early development: role of vitamin D. *Am J Physiol* 239:G473–G479
- Haverstick DM, Heady TN, Macdonald TL, Gray LS (2000) Inhibition of human prostate cancer proliferation in vitro and in a mouse model by a compound synthesized to block Ca²⁺ entry. *Cancer Res* 60:1002–1008
- Hellwig N, Albrecht N, Harteneck C, Schultz G, Schaefer M (2005) Homo- and heteromeric assembly of TRPV channel subunits. *J Cell Sci* 118:917–928
- Hirnet D, Olausson J, Fecher-Trost C, Boddig M, Nastainczyk W, Wissenbach U, Flockerzi V, Freichel M (2003) The TRPV6 gene, cDNA and protein. *Cell Calcium* 33:509–518
- Hoenderop JG, van der Kemp AW, Hartog A, van de Graaf SF, van Os CH, Willems PH, Bindels RJ (1999) Molecular identification of the apical Ca²⁺ channel in 1, 25-dihydroxyvitamin D₃-responsive epithelia. *J Biol Chem* 274:8375–8378
- Hoenderop JG, Vennekens R, Muller D, Prenen J, Droogmans G, Bindels RJ, Nilius B (2001) Function and expression of the epithelial Ca(2+) channel family: comparison of mammalian ECaC1 and 2. *J Physiol* 537:747–761
- Hoenderop JG, Nilius B, Bindels RJ (2003a) Epithelial calcium channels: from identification to function and regulation. *Pflugers Arch* 446:304–308
- Hoenderop JG, Voets T, Hoefs S, Weidema F, Prenen J, Nilius B, Bindels RJ (2003b) Homo- and heterotetrameric architecture of the epithelial Ca²⁺ channels TRPV5 and TRPV6. *EMBO J* 17:776–785
- Hoenderop JG, van Leeuwen JP, van der Eerden BC, Kersten FF, van der Kemp AW, Merillat AM, Waarsing JH, Rossier BC, Vallon V, Hummler E, Bindels RJ (2003c) Renal Ca²⁺ wasting, hyperabsorption, and reduced bone thickness in mice lacking TRPV5. *J Clin Invest* 112:1906–1914
- Hoenderop JG, Nilius B, Bindels RJ (2005) Calcium absorption across epithelia. *Physiol Rev* 85:373–422
- Hughes DA, Tang K, Strotmann R, Schoneberg T, Prenen J, Nilius B, Stoneking M (2008) Parallel selection on TRPV6 in human populations. *PLoS One* 3(2):e1686
- Huybers S, Naber TH, Bindels RJ, Hoenderop JG (2007) Prednisolone-induced Ca²⁺ malabsorption is caused by diminished expression of the epithelial Ca²⁺ channel TRPV6. *Am J Physiol Gastrointest Liver Physiol* 292:G92–G97
- Huybers S, Apostolaki M, van der Eerden BCJ, Kollias G, Naber THJ, Bindels RJM (2008) Hoenderop JGJ (2008) Murine TNFΔARE Crohn's Disease Model Displays Diminished Expression of Intestinal Ca²⁺ Transporters. *Inflamm Bowel Dis* 14:803–811
- Karaplis AC, Luz A, Glowacki J, Bronson RT, Tybulewicz VL, Kronenberg HM, Mulligan RC (1994) Lethal skeletal dysplasia from targeted disruption of the parathyroid hormone-related peptide gene. *Genes Dev* 8:277–289
- Kellett GL (2011) Alternative perspective on intestinal calcium absorption: proposed complementary actions of Ca(v)1.3 and TRPV6. *Nutr Rev* 69:347–370
- Kessler T, Wissenbach U, Grobholz R, Flockerzi V (2009) TRPV6 alleles do not influence prostate cancer progression. *BMC Cancer* 9:380
- Kim HJ, Yang DK, So I (2007) PDZ domain-containing protein as a physiological modulator of TRPV6. *Biochem Biophys Res Commun* 361:433–438

- Kim MH, Lee GS, Jung EM, Choi KC, Jeung EB (2009a) The negative effect of dexamethasone on calcium-processing gene expressions is associated with a glucocorticoid-induced calcium- absorbing disorder. *Life Sci* 85:146–152
- Kim MH, Lee GS, Jung EM, Choi KC, Oh GT, Jeung EB (2009b) Dexamethasone differentially regulates renal and duodenal calcium-processing genes in calbindin-D9k and -D28k knockout mice. *Exp Physiol* 94:138–151
- King N, Westbrook MJ, Young SL, Kuo A, Abedin M, Chapman J, Fairclough S, Hellsten U, Isogai Y, Letunic I, Marr M, Pincus D, Putnam N, Rokas A, Wright KJ, Zuzow R, Dirks W, Good M, Goodstein D, Lemons D, Li W, Lyons JB, Morris A, Nichols S, Richter DJ, Salamov A, Sequencing JG, Bork P, Lim WA, Manning G, Miller WT, McGinnis W, Shapiro H, Tjian R, Grigoriev IV, Rokhsar D (2008) The genome of the choanoflagellate *Monosiga brevicollis* and the origin of metazoans. *Nature* 451(7180):783–788
- Ko SH, Choi KC, Oh GT, Jeung EB (2009) Effect of dietary calcium and 1,25-(OH)₂D₃ on the expression of calcium transport genes in calbindin-D9k and -D28k double knockout mice. *Biochem Biophys Res Commun* 379:227–232
- Kovacs G, Montalbetti N, Simonin A, Danko T, Balazs B, Zsembery A, Hediger MA (2012) Inhibition of the human epithelial calcium channel TRPV6 by 2-aminoethoxydiphenyl borate (2-APB). *Cell Calcium* 52:468–480
- Kovacs G, Montalbetti N, Franz MC, Graeter S, Simonin A, Hediger MA (2013) Human TRPV5 and TRPV6: key players in cadmium and zinc toxicity. *Cell Calcium* 54(4):276–286
- Kovalevskaya NV, Schilderink N, Vuister GW (2011) Expression and purification of the C-terminal fragments of TRPV5/6 channels. *Protein Expr Purif* 80:28–33
- Kovalevskaya NV, Bokhovchuk FM, Vuister GW (2012) The TRPV5/6 calcium channels contain multiple calmodulin binding sites with differential binding properties. *J Struct Funct Genom* 13:91–100
- Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI (1997) Mutation of the mouse *klotho* gene leads to a syndrome resembling ageing. *Nature* 390:45–51
- Kutuzova GD, Sundersingh F, Vaughan J, Tadi BP, Ansay SE, Christakos S, Deluca HF (2008) TRPV6 is not required for 1 α ,25-dihydroxyvitamin D₃-induced intestinal calcium absorption in vivo. *Proc Natl Acad Sci USA* 105(50):19655–19659
- Lafond J, Leclerc M, Brunette MG (1991) Characterization of calcium transport by basal plasma membranes from human placental syncytiotrophoblast. *J Cell Physiol* 148:17–23
- Lambers TT, Weidema AF, Nilius B, Hoenderop JG, Bindels RJ (2004) Regulation of the mouse epithelial Ca²⁺ channel TRPV6 by the Ca²⁺-sensor calmodulin. *J Biol Chem* 279:28855–28861
- Lambers TT, Mahieu F, Oancea E, Hoofd L, de Lange F, Mensenkamp AR, Voets T, Nilius B, Clapham DE, Hoenderop JG, Bindels RJ (2006) Calbindin-D28K dynamically controls TRPV5-mediated Ca²⁺ transport. *EMBO J* 25:2978–2988
- Landowski CP, Bolanz KA, Suzuki Y, Hediger MA (2011) Chemical inhibitors of the calcium entry channel TRPV6. *Pharm Res* 28:322–330
- Lee GS, Jeung EB (2007) Uterine TRPV6 expression during the estrous cycle and pregnancy in a mouse model. *Am J Physiol Endocrinol Metab* 293:E132–E138
- Lee CT, Shang S, Lai LW, Yong KC, Lien YH (2004) Effect of thiazide on renal gene expression of apical calcium channels and calbindins. *Am J Physiol Renal Physiol* 287:F1164–F1170
- Lee GS, Lee KY, Choi KC, Ryu YH, Paik SG, Oh GT, Jeung EB (2007) Phenotype of a calbindin-D9k gene knockout is compensated for by the induction of other calcium transporter genes in a mouse model. *J Bone Miner Res* 22:1968–1978
- Lehen'kyi V, Flourakis M, Skryma R, Prevarskaya N (2007) TRPV6 channel controls prostate cancer cell proliferation via Ca²⁺/NFAT-dependent pathways. *Oncogene* 26:7380–7385
- Lehen'kyi V, Raphael M, Oulidi A, Flourakis M, Khalimonchuk S, Kondratskyi A, Gordienko DV, Mauroy B, Bonnal JL, Skryma R, Prevarskaya N (2011) TRPV6 determines the effect of vitamin D3 on prostate cancer cell growth. *PLoS One* 6(2):e16856

- Lehen'kyi V, Raphael M, Prevarskaya N (2012) The role of the TRPV6 channel in cancer. *J Physiol* 590:1369–1376
- Lieben L, Carmeliet G (2012) The involvement of TRP channels in bone homeostasis. *Front Endocrinol* 3:99
- Little R, Muimo R, Robson L, Harris K, Grabowski PS (2011) The transient receptor potential ion channel TRPV6 is expressed at low levels in osteoblasts and has little role in osteoblast calcium uptake. *PLoS One* 6(11):e28166
- Lu P, Boros S, Chang Q, Bindels RJ, Hoenderop JG (2008) The beta-glucuronidase klotho exclusively activates the epithelial Ca^{2+} channels TRPV5 and TRPV6. *Nephrol Dial Transplant* 23:3397–3402
- Merchant SS, Prochnik SE, Vallon O, Harris EH, Karpowicz SJ, Witman GB, Terry A, Salamov A, Fritz-Laylin LK, Marechal-Drouard L, Marshall WF, Qu LH, Nelson DR, Sanderfoot AA, Spalding MH, Kapitonov VV, Ren Q, Ferris P, Lindquist E, Shapiro H, Lucas SM, Grimwood J, Schmutz J, Cardol P, Cerutti H, Chanfreau G, Chen CL, Cognat V, Croft MT, Dent R, Dutcher S, Fernandez E, Fukuzawa H, Gonzalez-Ballester D, Gonzalez-Halphen D, Hallmann A, Hanikenne M, Hippler M, Inwood W, Jabbari K, Kalanon M, Kuras R, Lefebvre PA, Lemaire SD, Lobanov AV, Lohr M, Manuell A, Meier I, Mets L, Mittag M, Mittelmeier T, Moroney JV, Moseley J, Napoli C, Nedelcu AM, Niyogi K, Novoselov SV, Paulsen IT, Pazour G, Purton S, Ral JP, Riano-Pachon DM, Riekhof W, Rymarquis L, Schroda M, Stern D, Umen J, Willows R, Wilson N, Zimmer SL, Allmer J, Balk J, Bisova K, Chen CJ, Elias M, Gendler K, Hauser C, Lamb MR, Ledford H, Long JC, Minagawa J, Page MD, Pan J, Pootakham W, Roje S, Rose A, Stahlberg E, Terauchi AM, Yang P, Ball S, Bowler C, Dieckmann CL, Gladyshev VN, Green P, Jorgensen R, Mayfield S, Mueller-Roeber B, Rajamani S, Sayre RT, Brokstein P, Dubchak I, Goodstein D, Hornick L, Huang YW, Jhaveri J, Luo Y, Martinez D, Ngau WC, Otillar B, Poliakov A, Porter A, Szajkowski L, Werner G, Zhou K, Grigoriev IV, Rokhsar DS, Grossman AR (2007) The *Chlamydomonas* genome reveals the evolution of key animal and plant functions. *Science* 318(5848):245–250
- Moreau R, Daoud G, Bernatchez R, Simoneau L, Masse A, Lafond J (2002) Calcium uptake and calcium transporter expression by trophoblast cells from human term placenta. *Biochim Biophys Acta* 1564:325–332
- Muller D, Hoenderop JG, Merckx GF, van Os CH, Bindels RJ (2000) Gene structure and chromosomal mapping of human epithelial calcium channel. *Biochem Biophys Res Commun* 275:47–52
- Niemeyer BA, Bergs C, Wissenbach U, Flockerzi V, Trost C (2001) Competitive regulation of CaT-like-mediated Ca^{2+} entry by protein kinase C and calmodulin. *Proc Natl Acad Sci USA* 98(6):3600–3605
- Nijenhuis T, Hoenderop JG, van der Kemp AW, Bindels RJ (2003) Localization and regulation of the epithelial Ca^{2+} channel TRPV6 in the kidney. *J Am Soc Nephrol* 14:2731–2740
- Nilius B, Vennekens R, Prenen J, Hoenderop JG, Bindels RJ, Droogmans G (2000) Whole-cell and single channel monovalent cation currents through the novel rabbit epithelial Ca^{2+} channel ECaC. *J Physiol* 527(Pt 2):239–248
- Nilius B, Vennekens R, Prenen J, Hoenderop JG, Droogmans G, Bindels RJ (2001) The single pore residue Asp542 determines Ca^{2+} permeation and Mg^{2+} block of the epithelial Ca^{2+} channel. *J Biol Chem* 276:1020–1025
- Nilius B, Prenen J, Hoenderop JG, Vennekens R, Hoefs S, Weidema AF, Droogmans G, Bindels RJ (2002) Fast and slow inactivation kinetics of the Ca^{2+} channels ECaC1 and ECaC2 (TRPV5 and TRPV6). Role of the intracellular loop located between transmembrane segments 2 and 3. *J Biol Chem* 277:30852–30858
- Nilius B, Prenen J, Droogmans G, Voets T, Vennekens R, Freichel M, Wissenbach U, Flockerzi V (2003) Voltage dependence of the Ca^{2+} -activated cation channel TRPM4. *J Biol Chem* 278:30813–30820

- Okano T, Tsugawa N, Morishita A, Kato S (2004) Regulation of gene expression of epithelial calcium channels in intestine and kidney of mice by 1 α ,25-dihydroxyvitamin D₃. *J Steroid Biochem Mol Biol* 89–90:335–338
- Owsianik G, Talavera K, Voets T, Nilius B (2006) Permeation and selectivity of TRP channels. *Annu Rev Physiol* 68:685–717
- Oz OK, Hajibeigi A, Howard K, Cummins CL, van Abel M, Bindels RJ, Word RA, Kuro-o M, Pak CY, Zerwekh JE (2007) Aromatase deficiency causes altered expression of molecules critical for calcium reabsorption in the kidneys of female mice *. *J Bone Miner Res* 22:1893–1902
- Pahuja DN, DeLuca HF (1981) Stimulation of intestinal calcium transport and bone calcium mobilization by prolactin in vitamin D-deficient rats. *Science* 214(4524):1038–1039
- Peng JB (2011) TRPV5 and TRPV6 in transcellular Ca²⁺ transport: regulation, gene duplication, and polymorphisms in African populations. *Adv Exp Med Biol* 704:239–275
- Peng JB, Chen XZ, Berger UV, Vassilev PM, Tsukaguchi H, Brown EM, Hediger MA (1999) Molecular cloning and characterization of a channel-like transporter mediating intestinal calcium absorption. *J Biol Chem* 274:22739–22746
- Peng JB, Chen XZ, Berger UV, Weremowicz S, Morton CC, Vassilev PM, Brown EM, Hediger MA (2000) Human calcium transport protein CaT1. *Biochem Biophys Res Commun* 278:326–332
- Peng JB, Zhuang L, Berger UV, Adam RM, Williams BJ, Brown EM, Hediger MA, Freeman MR (2001) CaT1 expression correlates with tumor grade in prostate cancer. *Biochem Biophys Res Commun* 282(3):729–734
- Peters AA, Simpson PT, Bassett JJ, Lee JM, Da Silva L, Reid LE, Song S, Parat MO, Lakhani SR, Kenny PA, Roberts-Thomson SJ, Monteith GR (2012) Calcium channel TRPV6 as a potential therapeutic target in estrogen receptor-negative breast cancer. *Mol Cancer Ther* 11:2158–2168
- Phelps CB, Huang RJ, Lishko PV, Wang RR, Gaudet R (2008) Structural analyses of the ankyrin repeat domain of TRPV6 and related TRPV ion channels. *Biochemistry* 47:2476–2484
- Pike JW, Zella LA, Meyer MB, Fretz JA, Kim S (2007) Molecular actions of 1,25-dihydroxyvitamin D₃ on genes involved in calcium homeostasis. *J Bone Miner Res* 22 (Suppl 2):V16–V19
- Qiu A, Hogstrand C (2004) Functional characterisation and genomic analysis of an epithelial calcium channel (ECaC) from pufferfish, *Fugu rubripes*. *Gene* 342(1):113–123
- Schindl R, Fritsch R, Jardin I, Frischauf I, Kahr H, Muik M, Riedl MC, Groschner K, Romanin C (2012) Canonical transient receptor potential (TRPC) 1 acts as a negative regulator for vanilloid TRPV6-mediated Ca²⁺ influx. *J Biol Chem* 287:35612–35620
- Schoeber JP, Topala CN, Wang X, Diepens RJ, Lambers TT, Hoenderop JG, Bindels RJ (2006) RGS2 inhibits the epithelial Ca²⁺ channel TRPV6. *J Biol Chem* 281:29669–29674
- Schoeber JP, Topala CN, Lee KP, Lambers TT, Ricard G, van der Kemp AW, Huynen MA, Hoenderop JG, Bindels RJ (2008) Identification of Nipsnap1 as a novel auxiliary protein inhibiting TRPV6 activity. *Pflugers Arch* 457:91–101
- Schwarz EC, Wissenbach U, Niemeyer BA, Strauss B, Philipp SE, Flockerzi V, Hoth M (2006) TRPV6 potentiates calcium-dependent cell proliferation. *Cell Calcium* 39:163–173
- Semenova SB, Vassilieva IO, Fomina AF, Runov AL, Negulyaev YA (2009) Endogenous expression of TRPV5 and TRPV6 calcium channels in human leukemia K562 cells. *Am J Physiol Cell Physiol* 296:C1098–C1104
- Sibai BM (2005) Diagnosis, prevention, and management of eclampsia. *Obstet Gynecol* 105:402–410
- Sibley CP, Boyd RD (1988) Control of transfer across the mature placenta. *Oxf Rev Reprod Biol* 10:382–435
- Soejima M, Tachida H, Koda Y (2009) Sequence analysis of human TRPV6 suggests positive selection outside Africa. *Biochem Genet* 47:147–153
- Song Y, Peng X, Porta A, Takanaga H, Peng JB, Hediger MA, Fleet JC, Christakos S (2003) Calcium transporter 1 and epithelial calcium channel messenger ribonucleic acid are

- differentially regulated by 1,25 dihydroxyvitamin D₃ in the intestine and kidney of mice. *Endocrinology* 144(9):3885–3894
- Stajich JE, Hahn MW (2005) Disentangling the effects of demography and selection in human history. *Mol Biol Evol* 22:63–73
- Sternfeld L, Anderie I, Schmid A, Al-Shaladi H, Krause E, Magg T, Schreiner D, Hofer HW, Schulz I (2007) Identification of tyrosines in the putative regulatory site of the Ca²⁺ channel TRPV6. *Cell Calcium* 42:91–102
- Stumpf T, Zhang Q, Hirnet D, Lewandrowski U, Sickmann A, Wissenbach U, Dorr J, Lohr C, Deitmer JW, Fecher-Trost C (2008) The human TRPV6 channel protein is associated with cyclophilin B in human placenta. *J Biol Chem* 283:18086–18098
- Sudo Y, Matsuo K, Tetsuo T, Tsutsumi S, Ohkura M, Nakai J, Uezono Y (2010) Derived (mutated)-types of TRPV6 channels elicit greater Ca²⁺ influx into the cells than ancestral-types of TRPV6: evidence from *Xenopus* oocytes and mammalian cell expression system. *J Pharmacol Sci* 114:281–291
- Suzuki Y, Kovacs CS, Takanaga H, Peng JB, Landowski CP, Hediger MA (2008a) Calcium channel TRPV6 is involved in murine maternal-fetal calcium transport. *J Bone Miner Res* 23:1249–1256
- Suzuki Y, Pasch A, Bonny O, Mohaupt MG, Hediger MA, Frey FJ (2008b) Gain-of-function haplotype in the epithelial calcium channel TRPV6 is a risk factor for renal calcium stone formation. *Hum Mol Genet* 17:1613–1618
- Suzuki Y, Landowski CP, Hediger MA (2008c) Mechanisms and regulation of epithelial Ca²⁺ absorption in health and disease. *Annu Rev Physiol* 70:257–271
- Taira M, Iizasa T, Shimada H, Kudoh J, Shimizu N, Tatibana M (1990) A human testis-specific mRNA for phosphoribosylpyrophosphate synthetase that initiates from a non-AUG codon. *J Biol Chem* 265:16491–16497
- Taparia S, Fleet JC, Peng JB, Wang XD, Wood RJ (2006) 1,25-Dihydroxyvitamin D and 25-hydroxyvitamin D-mediated regulation of TRPV6 (a putative epithelial calcium channel) mRNA expression in Caco-2 cells. *Eur J Nutr* 45:196–204
- Thyagarajan B, Lukacs V, Rohacs T (2008) Hydrolysis of phosphatidylinositol 4,5-bisphosphate mediates calcium-induced inactivation of TRPV6 channels. *J Biol Chem* 283:14980–14987
- Tobias JH, Cooper C (2004) PTH/PTHrP activity and the programming of skeletal development in utero. *J Bone Miner Res* 19:177–182
- van Abel M, Hoenderop JG, van der Kemp AW, van Leeuwen JP, Bindels RJ (2003) Regulation of the epithelial Ca²⁺ channels in small intestine as studied by quantitative mRNA detection. *Am J Physiol Gastrointest Liver Physiol* 285:G78–G85
- van Abel M, Hoenderop JG, Bindels RJ (2005) The epithelial calcium channels TRPV5 and TRPV6: regulation and implications for disease. *Naunyn Schmiedebergs Arch Pharmacol* 371:295–306
- Van Cromphaut SJ, Rummens K, Stockmans I, Van Herck E, Dijcks FA, Ederveen AG, Carmeliet P, Verhaeghe J, Bouillon R, Carmeliet G (2003) Intestinal calcium transporter genes are upregulated by estrogens and the reproductive cycle through vitamin D receptor-independent mechanisms. *J Bone Miner Res* 18:1725–1736
- Van Cromphaut SJ, Stockmans I, Torrekens S, Van Herck E, Carmeliet G, Bouillon R (2007) Duodenal calcium absorption in dexamethasone-treated mice: functional and molecular aspects. *Arch Biochem Biophys* 460:300–305
- van de Graaf SF, Hoenderop JG, Gkika D, Lamers D, Prenen J, Rescher U, Gerke V, Staub O, Nilius B, Bindels RJ (2003) Functional expression of the epithelial Ca²⁺ channels (TRPV5 and TRPV6) requires association of the S100A10-annexin 2 complex. *EMBO J* 22:1478–1487
- van de Graaf SF, Chang Q, Mensenkamp AR, Hoenderop JG, Bindels RJ (2006a) Direct interaction with Rab11a targets the epithelial Ca²⁺ channels TRPV5 and TRPV6 to the plasma membrane. *Mol Cell Biol* 26:303–312
- van de Graaf SF, Hoenderop JG, Bindels RJ (2006b) Regulation of TRPV5 and TRPV6 by associated proteins. *Am J Physiol Renal Physiol* 290:F1295–F1302

- van de Graaf SF, van der Kemp AW, van den Berg D, van Oorschot M, Hoenderop JG, Bindels RJ (2006c) Identification of BSPRY as a novel auxiliary protein inhibiting TRPV5 activity. *J Am Soc Nephrol* 17:26–30
- van der Eerden BC, Hoenderop JG, de Vries TJ, Schoenmaker T, Buurman CJ, Uitterlinden AG, Pols HA, Bindels RJ, van Leeuwen JP (2005) The epithelial Ca²⁺ channel TRPV5 is essential for proper osteoclastic bone resorption. *Proc Natl Acad Sci USA* 102:17507–17512
- van der Eerden BC, Weissgerber P, Fratzl-Zelman N, Olausson J, Hoenderop JG, Schreuders-Koedam M, Eijken M, Roschger P, de Vries TJ, Chiba H, Klaushofer K, Flockerzi V, Bindels RJ, Freichel M, van Leeuwen JP (2012) The transient receptor potential channel TRPV6 is dynamically expressed in bone cells but is not crucial for bone mineralization in mice. *J Cell Physiol* 227:1951–1959
- Vassilev PM, Peng JB, Johnson J, Hediger MA, Brown EM (2001) Inhibition of CaT1 channel activity by a noncompetitive IP₃ antagonist. *Biochem Biophys Res Commun* 280:145–150
- Vennekens R, Hoenderop JG, Prenen J, Stuiver M, Willems PH, Droogmans G, Nilius B, Bindels RJ (2000) Permeation and gating properties of the novel epithelial Ca²⁺ channel. *J Biol Chem* 275:3963–3969
- Vennekens R, Owsianik G, Nilius B (2008) Vanilloid transient receptor potential cation channels: an overview. *Curr Pharm Des* 14:18–31
- Voets T, Prenen J, Fleig A, Vennekens R, Watanabe H, Hoenderop JG, Bindels RJ, Droogmans G, Penner R, Nilius B (2001) CaT1 and the calcium release-activated calcium channel manifest distinct pore properties. *J Biol Chem* 276:47767–47770
- Voets T, Janssens A, Prenen J, Droogmans G, Nilius B (2003) Mg²⁺-dependent gating and strong inward rectification of the cation channel TRPV6. *J Gen Physiol* 121:245–260
- Voets T, Janssens A, Droogmans G, Nilius B (2004) Outer pore architecture of a Ca²⁺-selective TRP channel. *J Biol Chem* 279:15223–15230
- Walker JJ (2000) Pre-eclampsia. *Lancet* 356:1260–1265
- Walters JR, Balesaria S, Chavele KM, Taylor V, Berry JL, Khair U, Barley NF, van Heel DA, Field J, Hayat JO, Bhattacharjee A, Jeffery R, Poulosom R (2006) Calcium channel TRPV6 expression in human duodenum: different relationships to the vitamin D system and aging in men and women. *J Bone Miner Res* 21:1770–1777
- Wangemann P, Nakaya K, Wu T, Maganti RJ, Itza EM, Sanneman JD, Harbidge DG, Billings S, Marcus DC (2007) Loss of cochlear HCO₃ secretion causes deafness via endolymphatic acidification and inhibition of Ca²⁺ reabsorption in a Pendred syndrome mouse model. *Am J Physiol Renal Physiol* 292:F1345–F1353
- Weissgerber P, Kriebis U, Tsvilovskyy V, Olausson J, Kretz O, Stoerger C, Vennekens R, Wissenbach U, Middendorff R, Flockerzi V, Freichel M (2011) Male fertility depends on Ca²⁺ absorption by TRPV6 in epididymal epithelia. *Sci Signal* 4(171):ra2
- Weissgerber P, Kriebis U, Tsvilovskyy V, Olausson J, Kretz O, Stoerger C, Mannebach S, Wissenbach U, Vennekens R, Middendorff R, Flockerzi V, Freichel M (2012) Excision of the Trpv6 gene leads to severe defects in epididymal Ca²⁺ absorption and male fertility much alike the single D541A pore mutation. *J Biol Chem* 287:17930–17941
- Wissenbach U (2013) Pathologies of Ca²⁺ channels. Springer, Berlin
- Wissenbach U, Niemeyer BA (2007) Trpv6. *Handb Exp Pharmacol* 179(179):221–234
- Wissenbach U, Niemeyer BA, Fixemer T, Schneidewind A, Trost C, Cavalie A, Reus K, Meese E, Bonkhoff H, Flockerzi V (2001) Expression of CaT-like, a novel calcium-selective channel, correlates with the malignancy of prostate cancer. *J Biol Chem* 276:19461–19468
- Wissenbach U, Niemeyer B, Himmerkus N, Fixemer T, Bonkhoff H, Flockerzi V (2004) TRPV6 and prostate cancer: cancer growth beyond the prostate correlates with increased TRPV6 Ca²⁺ channel expression. *Biochem Biophys Res Commun* 322:1359–1363
- Wood RJ, Tchack L, Taparia S (2001) 1,25-Dihydroxyvitamin D₃ increases the expression of the CaT1 epithelial calcium channel in the Caco-2 human intestinal cell line. *BMC Physiol* 1:11

- Woudenberg-Vrenken TE, Lameris AL, Weissgerber P, Olausson J, Flockerzi V, Bindels RJ, Freichel M, Hoenderop JG (2012) Functional TRPV6 channels are crucial for transepithelial Ca^{2+} absorption. *Am J Physiol Gastrointest Liver Physiol* 303:G879–G885
- Wu G, Zhang W, Na T, Jing H, Wu H, Peng JB (2012) Suppression of intestinal calcium entry channel TRPV6 by OCRL, a lipid phosphatase associated with Lowe syndrome and Dent disease. *Am J Physiol Cell Physiol* 302:C1479–C1491
- Yang S-S, Lo Y-F, Yu I-S, Lin S-W, Chang T-H, Hsu Y-J, Chao T-K, Sytwu H-K, Uchida S, Sasaki S, Lin S-H (2010) Generation and analysis of the thiazide-sensitive Na/Cl cotransporter (Ncc/Slc12a3) Ser707X knockin mouse as a model of Gitelman syndrome. *Hum Mutat* 31:1304–1315
- Yang H, Kim TH, An BS, Choi KC, Lee HH, Kim JM, Jeung EB (2013) Differential expression of calcium transport channels in placenta primary cells and tissues derived from preeclamptic placenta. *Mol Cell Endocrinol* 367:21–30
- Zakharian E, Cao C, Rohacs T (2011) Intracellular ATP supports TRPV6 activity via lipid kinases and the generation of PtdIns(4,5) P. *FASEB J* 25:3915–3928
- Zheng XE, Wang Z, Liao MZ, Lin YS, Shuhart MC, Schuetz EG, Thummel KE (2012) Human PXR-mediated induction of intestinal CYP3A4 attenuates 1 α ,25-dihydroxyvitamin D (3) function in human colon adenocarcinoma LS180 cells. *Biochem Pharmacol* 84:391–401
- Zhuang L, Peng JB, Tou L, Takanaga H, Adam RM, Hediger MA, Freeman MR (2002) Calcium-selective ion channel, CaT1, is apically localized in gastrointestinal tract epithelia and is aberrantly expressed in human malignancies. *Lab Invest* 82:1755–1764